



Malmö 28 April 2023

PRESS RELEASE

BioStock article: Aptahem on the need for more effective sepsis treatments

Biotechnology company Aptahem is developing Aptahem-1, a drug candidate whose purpose is to reduce the high mortality and severe tissue damage that can occur in sepsis. BioStock contacted Luiza Jedlina, Chief Scientific Officer and co-founder of Aptahem, to talk about the need for better treatment options than antibiotics.

Read the full interview with Luiza Jedlina at [biostock.se](https://www.biostock.se):

<https://www.biostock.se/en/2023/04/aptahem-on-the-need-for-more-effective-sepsis-treatments/>

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Aptahem-1, is currently in early clinical phase. Aptahem-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.